OCUL - Company ID 0001393434
OCULAR THERAPEUTIX, INC trades as OCUL and has a market capitalization of $2.23 B, making it the #2046 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $51.95M, down 18.5% from the prior year and net income of -$265.94M. This page tracks OCULAR THERAPEUTIX, INC through 827 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-12
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years OCULAR THERAPEUTIX, INC's revenue grew from $1.89M to $51.95M, a compound annual growth rate of 44.5%. Net profit margin expanded from -2369.0% to -511.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-26 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Proxy materials | DEFA14A | 2026-04-30 |
The largest companies sharing OCULAR THERAPEUTIX, INC's SEC industry classification (pharmaceutical preparations).
OCULAR THERAPEUTIX, INC (OCUL) has a market capitalization of $2.23 B as of 2026-07-12, ranking #2046 among US-listed companies.
OCULAR THERAPEUTIX, INC reported revenue of $51.95M for fiscal year 2025, a decrease of 18.5% year over year.
In its latest fiscal year OCULAR THERAPEUTIX, INC reported a net loss of $265.94M.